Phototherapeutic keratectomy with mitomycin C after Descemet stripping automated endothelial keratoplasty

• Published in: British journal of ophthalmology Vol. 94; no. 3; pp. 377 - 378
• Main Authors: Hongyok, Teeravee, Kim, Alisa, Jun, Albert S, Ladas, John G, Chuck, Roy S
• Format: Journal Article
• Language: English
• Published: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.03.2010; BMJ Publishing Group LTD
• Subjects: Aged, 80 and over; Automation; Cataracts; Combined Modality Therapy; Cornea; Corneal Opacity - therapy; Descemet Stripping Endothelial Keratoplasty - methods; Female; Humans; Lasers; Male; Mitomycin - therapeutic use; Photorefractive Keratectomy - methods; treatment lasers; treatment surgery
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjo.2009.165951

Comment SEF can occur in advanced endothelial diseases, often with profound visual loss caused by active fibroblasts and increased collagen deposition. 3 In some cases, SEF could be masked by corneal oedema and considered as not visually significant during initial visits but became more prominent after DSAEK when stromal oedema subsided. Early studies demonstrated haze, and even severe scarring. 1 The adjunctive topical MMC 0.02% is a promising method for scar prevention in high-risk eyes undergoing excimer laser surface ablations, including after PK. 5 Recent study demonstrated no endothelial toxicity after prophylactic use. 6 In our patients, we demonstrated successful improvement of corneal clarity, vision and prevention of SEF for up to 12 months after treatment with no delayed epithelial wound healing or corneal oedema.